NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $146,846 | +42.4% | 246,800 | +37.6% | 0.00% | – |
| Q2 2023 | $103,132 | -43.0% | 179,360 | -30.4% | 0.00% | – |
| Q1 2023 | $180,820 | -59.4% | 257,579 | +30.6% | 0.00% | – |
| Q4 2022 | $445,830 | -62.8% | 197,270 | -47.4% | 0.00% | – |
| Q3 2022 | $1,198,000 | -2.8% | 374,767 | +15.6% | 0.00% | – |
| Q2 2022 | $1,232,000 | +244.1% | 324,199 | +387.9% | 0.00% | – |
| Q1 2022 | $358,000 | -78.4% | 66,453 | -45.8% | 0.00% | – |
| Q4 2021 | $1,655,000 | -47.1% | 122,523 | -29.7% | 0.00% | – |
| Q3 2021 | $3,130,000 | +39.3% | 174,274 | +33.2% | 0.00% | – |
| Q2 2021 | $2,247,000 | 0.0% | 130,880 | +16.5% | 0.00% | – |
| Q1 2021 | $2,247,000 | +25.8% | 112,374 | +6.9% | 0.00% | – |
| Q4 2020 | $1,786,000 | -4.3% | 105,083 | -6.5% | 0.00% | – |
| Q3 2020 | $1,866,000 | -46.8% | 112,419 | -25.8% | 0.00% | -100.0% |
| Q2 2020 | $3,508,000 | +4.1% | 151,464 | -19.8% | 0.00% | 0.0% |
| Q1 2020 | $3,370,000 | -7.8% | 188,830 | +11.5% | 0.00% | 0.0% |
| Q4 2019 | $3,656,000 | -38.1% | 169,367 | -47.8% | 0.00% | 0.0% |
| Q3 2019 | $5,911,000 | -46.8% | 324,541 | +3.9% | 0.00% | -50.0% |
| Q2 2019 | $11,112,000 | +67.0% | 312,286 | +57.7% | 0.00% | +100.0% |
| Q1 2019 | $6,654,000 | +18.0% | 198,066 | +15.4% | 0.00% | 0.0% |
| Q4 2018 | $5,641,000 | -52.3% | 171,606 | -11.6% | 0.00% | -50.0% |
| Q3 2018 | $11,829,000 | -13.0% | 194,035 | -30.4% | 0.00% | 0.0% |
| Q2 2018 | $13,604,000 | -91.3% | 278,634 | -81.1% | 0.00% | -92.6% |
| Q1 2018 | $156,946,000 | +584.8% | 1,477,003 | +284.8% | 0.03% | +575.0% |
| Q4 2017 | $22,920,000 | +75.0% | 383,787 | -29.7% | 0.00% | +100.0% |
| Q3 2017 | $13,096,000 | +66.0% | 545,701 | +35.2% | 0.00% | 0.0% |
| Q2 2017 | $7,890,000 | +21.5% | 403,574 | +45.9% | 0.00% | +100.0% |
| Q1 2017 | $6,493,000 | +282.6% | 276,642 | +100.0% | 0.00% | – |
| Q4 2016 | $1,697,000 | +344.2% | 138,312 | +522.2% | 0.00% | – |
| Q3 2016 | $382,000 | +9.1% | 22,228 | -9.7% | 0.00% | – |
| Q2 2016 | $350,000 | +117.4% | 24,622 | +109.8% | 0.00% | – |
| Q1 2016 | $161,000 | -87.2% | 11,734 | -84.3% | 0.00% | – |
| Q4 2015 | $1,258,000 | +195.3% | 74,626 | +91.4% | 0.00% | – |
| Q3 2015 | $426,000 | -76.4% | 38,987 | -72.9% | 0.00% | -100.0% |
| Q2 2015 | $1,802,000 | +2152.5% | 144,033 | +1865.8% | 0.00% | – |
| Q1 2015 | $80,000 | -27.3% | 7,327 | +4.1% | 0.00% | – |
| Q4 2014 | $110,000 | -71.1% | 7,036 | -77.7% | 0.00% | – |
| Q3 2014 | $380,000 | +313.0% | 31,495 | +339.3% | 0.00% | – |
| Q2 2014 | $92,000 | -58.0% | 7,170 | -60.2% | 0.00% | – |
| Q1 2014 | $219,000 | -41.1% | 18,035 | -44.9% | 0.00% | – |
| Q4 2013 | $372,000 | -63.6% | 32,706 | -66.6% | 0.00% | – |
| Q3 2013 | $1,022,000 | +40.8% | 97,904 | +55.7% | 0.00% | – |
| Q2 2013 | $726,000 | – | 62,869 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |